|Original language||English (US)|
|Number of pages||2|
|State||Published - Nov 2011|
Bibliographical noteFunding Information:
This work was supported by NIH grants (5R01HD052074-05 and 5R01MH086000-01A2). Dr SH Fatemi has received patents for use of Reelin as a diagnostic marker for psychiatric disorders. He has not derived any financial gains from these patents. Dr SH Fatemi acknowledges the critical review of this commentary by T Folsom, R Kneeland, S Liesch, and Dr M Karkhane Yousefi.